UCB Expands Use of Genedata Software to Manage Biologics Lead Discovery Information

Basel, Switzerland, December 15, 2008

Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, announces an expansion of its research informatics collaboration with the global biopharmaceutical company UCB. The two companies have collaborated since 2006 with a focus on enhancing the management of drug target and biomarker discovery data using the Genedata Phylosopher® and Genedata Expressionist® platforms.

The collaboration has been renewed and expanded and now also supports UCB’s biologics and lead-finding activities in the fields of central nervous system disorders and autoimmune and inflammatory disorders research conducted in the UK and Belgium.

The extended collaboration aims to further expand the established platform from target discovery functionalities to lead generation support. For this advance, the Genedata Phylosopher platform is now additionally being used for storing proprietary drug candidate information produced by UCB’s biologics discovery efforts. As such, the Phylosopher database now relates therapeutic targets to protein-based drug leads, as well as sequence-based biologics reference data. This allows scientists to make better and faster drug discovery and development decisions.

In addition, Genedata Expressionist functionalities have been expanded to include data from much of UCB’s molecular profiling technology portfolio. Scientists can now review and explore multiple data types in one space to make better and faster decisions.

“Our decision to combine Genedata’s software products with our in-house customized software has been driven by the trust that we have developed in their established product line. This marriage has allowed us to leverage capabilities of both systems to support the generation of scientific insight more efficiently,” said Dr. Phil Scordis, UCB senior group leader, Informatics. “We are pleased that we can work with Genedata as an experienced partner. It has been important to the progress of these activities that Genedata’s software products can be easily integrated into our existing infrastructure.”

“We are proud that we have been able to expand and diversify our relationship with UCB, a leading global biopharmaceutical company,” said Dr. Othmar Pfannes, CEO of Genedata. “Our collaboration with UCB is an excellent showcase of how Genedata’s products can meet a company’s specific needs for both small and large molecule drug discovery.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).

Contact
Allison Kurz
Genedata
Marketing & Communications
Phone: +41 61 511 8459
communications@genedata.com

Jackie Thrasivoulos
Genedata
Public Relations
Phone: +1 508 881 3109
jackie.thrasivoulos@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.